Easterseals Capital Region & Eastern Connecticut is proud to announce that it is the first provider in the state to offer the EarliPoint™ Evaluation to identify autism spectrum disorder (ASD) in children as young as 16 months.
Developed by EarliTec Diagnostics, this innovative and FDA-authorized diagnostic tool captures a child’s social-visual engagement patterns imperceptible to the human eye, facilitating faster and more objective diagnoses of ASD compared to traditional methods. “This innovative technology, combined with a child’s developmental history and clinical assessment, allows us to quickly identify young children with and at-risk for autism,” said Dr. Nicole M. Barcelos, Psy.D., Director of Clinical Services at Easterseals Capital Region & Eastern CT. “Early identification is crucial for timely access to services and tailored care plans.”
How the EarliPoint Evaluation Works:
- They Watch: Children watch brief video scenes of social interactions while their looking behavior is monitored.
- EarliPoint Detects: The device uses Dynamic Quantification of Social-Visual Engagement to capture and analyze behavior imperceptible to the human eye.
- Providers Diagnose: Clinicians receive precise, objective data to evaluate autism and understand a child’s social and cognitive behaviors.
“Easterseals is proud to be at the forefront of offering the groundbreaking EarliPoint™ Evaluation, our commitment at Easterseals is always to provide the highest quality care and support,” said Robin Sharp, President and CEO of Easterseals Capital Region & Eastern CT. “This will mean so much for Connecticut families in getting the knowledge and resources they need for their children to succeed.”
Nationwide, the average age of autism diagnosis is 4 to 5 years, delaying critical early interventions that could positively influence a child’s developmental outcomes. The EarliPoint™ Evaluation offers actionable insights that enables Easterseals clinicians to:
- Diagnose ASD in children as young as 16 months.
- Streamline evaluations, reducing wait times and eliminating exhaustive traditional assessments.
- Quickly inform parents and providers of findings after a single evaluation session.
- Identify early signs of developmental and behavioral concerns, allowing for personalized care plans.
With FDA clearance and demonstrated clinical reliability, the EarliPoint™ Evaluation marks a significant advancement in autism diagnosis and care. Easterseals Capital Region & Eastern CT’s leadership in offering this innovative service underscores its commitment to enhancing the lives of children and families across the state.
For more information about the EarliPoint Evaluation, please contact Easterseals Capital Region & Eastern CT at medrehab@escrec.org or call 860-270-0600.
